Catecholamine storage

"Catecholamine storage" refers to the **biological process** by which monoamines such as dopamine, norepinephrine, and epinephrine are sequestered within intracellular vesicles in neurons and chromaffin cells. This is not a single molecular target but rather a physiological mechanism involving several key proteins—most notably **vesicular monoamine transporter 2** (**VMAT2**)—which actively transports cytosolic catecholamines into acidic secretory vesicles for safe containment until exocytotic release[1][4]. The low pH inside these vesicles traps ionized forms of catecholamines so they cannot diffuse out[1]. Storage is essential for regulated neurotransmission; disruption can lead to increased cytosolic degradation by enzymes such as monoamine oxidase (**MAO**) or altered synaptic signaling[3]. Pharmacologically relevant targets within this system include VMAT2—which can be inhibited by drugs like reserpine—and enzymes involved in synthesis/degradation pathways. However, "catecholamine storage" itself is not considered a canonical drug target but rather describes an important step in neurotransmitter handling[1][3]. In summary: **Catecholamine storage is not a specific molecule or receptor but describes an essential cellular function mediated primarily by VMAT2 and associated with normal neuronal signaling. It should not be listed as a therapeutic target per se.**

Other names

Catecholamine vesicular storageMonoamine storageVesicular catecholamine accumulation